NCT03217669 2023-05-03
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
University of Kansas Medical Center
Phase 1 Unknown
Clinical Trials
8 trialsNCT03589651 2023-02-21
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT03471286 2021-08-26
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02559492 2019-09-25
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT01195311 2018-01-17
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02298153 2017-12-11
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
Incyte Corporation
Phase 1 Terminated
NCT02118285 2017-12-05
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed